CBD vs. CBG for Migraines: Which Works Better
Migraine disease is a systemic neurological event. It involves a hyperexcitable brain, a volatile trigeminal nerve system, and a rapid-fire cascade of inflammatory neuropeptides. Standard pain relief often hits a wall because it ignores the underlying endocannabinoid deficiency that may be fueling the process.
By Genevieve
By looking at CBD (Cannabidiol) and CBG (Cannabigerol) as distinct tools rather than generic "cannabis supplements," you can build a protocol that addresses the migraine at the root.
Key Takeaways for Migraine Relief
- Clinical Endocannabinoid Deficiency (CECD): Chronic migraineurs often have lower levels of anandamide, the body’s "bliss molecule," which may leave pain signals unchecked.
- CBD for Prevention: Acts as a daily prophylactic, potentially influencing serotonin receptors to stabilize the brain’s threshold for attacks.
- CBG for Inflammation: Targets neuro-inflammation and sensory nerves, supporting the body against the "aura" phase.
- The Terpene Factor: Beta-Caryophyllene acts as a key to CB2 receptors, helping to dampen trigeminal nerve pain.
- Consistency Over Potency: High doses of THC can sometimes trigger rebound headaches. A low-dose, stable intake supports neurological balance.
The Science of the Migraine Brain
Think of your Endocannabinoid System (ECS) as the brain's dimmer switch. When that system is taxed—or under-resourced—it fails to modulate pain signals effectively. Patients with chronic migraines frequently show a deficiency in anandamide within their spinal fluid. Introducing phytocannabinoids may support the body’s internal regulatory system, providing the missing chemistry needed to help keep neurons from firing out of control.
CBD vs. CBG: Choosing Your Protocol
You don’t use a hammer for a surgical procedure, and you shouldn’t use the same cannabinoid for every stage of a migraine.
CBD: The Serotonin Regulator
CBD is a daily foundation. It interacts with 5-HT1A serotonin receptors—the same targets as many prescription abortive medications.
- Stabilizes Triggers: It buffers the nervous system against stress, which is a primary trigger for many.
- CGRP Modulation: It may limit the release of Calcitonin Gene-Related Peptide (CGRP), a protein associated with pulsing migraine pain.
- Neuroprotection: It provides a consistent, calming layer of support for over-sensitive neurons.
CBG: The Neuro-Anti-Inflammatory
CBG is a specialist. It is an alpha-2 adrenergic receptor agonist and a GABA uptake inhibitor, which may be effective for the physical manifestations of an attack.
- Muscle Relaxation: By inhibiting GABA uptake, it supports the release of neck and shoulder tension that often acts as a precursor to a migraine.
- Vasodilation Control: It assists in regulating the blood vessel fluctuations that may cause intracranial pressure.
- Nausea Management: Early clinical data suggest CBG may be helpful for calming the stomach during an aura.
| Feature | CBD (Cannabidiol) | CBG (Cannabigerol) |
|---|---|---|
| Primary Target | 5-HT1A (Serotonin) | Alpha-2 / GABA / COX-2 |
| Best Use Case | Daily prevention & stress | Acute tension & neuro-inflammation |
| Nausea Impact | Moderate | High |
| Experience | Grounding/Calming | Focused/Physically Relaxing |
Inhibiting the Trigeminal Nerve
When the trigeminal nerve is overstimulated, it triggers a flood of CGRP, causing cranial blood vessels to swell and throb. Research suggests that pairing CBD with Beta-Caryophyllene can naturally inhibit this nerve's excitability. Because Beta-Caryophyllene binds directly to CB2 receptors on the trigeminal nerve, it may stop the pain cascade at the source.
Managing the Post-drome "Hangover"
The "brain fog" that follows a migraine is physically draining. To clear this, focus on specific terpenes:
- Alpha-Pinene: Acts as an acetylcholinesterase inhibitor to support focus and cut through post-migraine sluggishness.
- Humulene: Works alongside Caryophyllene to resolve lingering inflammation in the brain's lining after an attack.
Strategic Dosing: Prevention vs. Rescue
The Daily Prophylactic
- Dose: 25mg CBD + 10mg CBG.
- Method: Full-spectrum oil or capsules taken every morning.
- Goal: Raise the brain’s "threshold" to keep neurons stable.
The Rescue Dose
- Dose: A 1:1 THC:CBD ratio or high-CBD flower.
- Method: Dry herb vaporization or sublingual nano-emulsions.
- Goal: Immediate systemic relief. Inhalation works in about 90 seconds, bypassing the digestive tract, which often shuts down during an active migraine attack.
Safety and Drug Interactions
CBD and CBG are metabolized by the Cytochrome P450 enzyme system in the liver. This is the same pathway used by many common prescriptions.
Consult a healthcare provider if you take:
- Propranolol (Beta-blockers)
- Amitriptyline (Antidepressants)
- NSAIDs (like Ibuprofen or Naproxen)
If your medication carries a "Grapefruit Warning," treat cannabinoids with the same caution. Start low, monitor your symptoms, and keep your healthcare provider in the loop.
Lifestyle Integration
Treat this like a personal trial: track your triggers alongside your intake. Note whether your aura duration shortens or your headache-free days increase. Remember that CBG can be slightly energizing, making it better for daytime use, while CBD is ideal for the evening to support the restorative sleep cycles necessary for neurological recovery.
Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.
Sources
-
Russo EB. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 25(1-2):31-9. PubMed
-
Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed
-
Aviram J, Samuelly-Leichtag G. (2017). Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomised controlled trials. Pain Physician. 20(6):E755-E796. PubMed
-
Borrelli F, Fasolino I, Romano B, et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 85(9):1306-16. PubMed
-
Mlost J, Bryk M, Starowicz K. (2020). Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 21(22):8870. PubMed
Ready to find your strain?
Add your strains, pick your effects — we'll rank them.